Minimize Uncertainty – Make Informed Decisions – Succeed

Cell_Gene_Therapy

Cell and Gene Therapy Today—January 22, 2026

January 22, 2026gene therapy,astrazeneca,Duchenne Muscular Dystrophy,BioPharma and Tech News,Parkinson's Disease,CAR T Therapy,Cell and Gene Therapy News,Inherited retinal diseases,CAR-NK therapy,cell therapy manufacturingWaldenström lymphoma,ImmunityBio

This week’s updates highlight significant advancements in gene and cell…

by LucidQuest

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Insilico and Hygtia partner on brain-penetrant NLRP3 inhibitor

January 22, 2026CNS,clinical development,Parkinson's Disease,biopharma,neuroinflammation,Lucid Diligence Brief,payer access,diligence,partnerships,AI in drug discoveryNLRP3

Lucid Diligence Brief: Insilico and Hygtia partner on brain-penetrant NLRP3…

by Timos Papagatsias

Rare Disease news

Rare Disease Today—January 22, 2026

January 22, 2026gene therapy,Duchenne Muscular Dystrophy,BioPharma and Tech News,Idiopathic Pulmonary Fibrosis,Orphan Drug Designation,Cushing’s disease,Rare Disease News,Pompe disease,ErythromelalgiaSobi,Aspaveli

This week's updates focus on significant regulatory approvals, orphan drug…

by LucidQuest

Neuroscience

Neuroscience Video Recap—January 21, 2026

January 21, 2026Elismetrep,Axsome Therapeutics,Teva,AJOVY,Alzheimer's Disease,Lumateperone,novartis,SciNeuro,BioPharma and Tech News,Dyno Therapeutics,obesity,Alto Neuroscience,Fibromyalgia,Pediatric episodic migraine,Alpha Mannosidosis,Ramzede,Johnson & Johnson,Velmanase alfa,Caplyta,Pramipexole,Neuroscience News,Ondansetron,Chiesi,Esreboxetine,Major depressive disorderFremanezumab,Kallyope

This Neuroscience video recap highlights key developments across regulatory…

by LucidQuest

Immunology

Immunology Today—January 21, 2026

January 21, 2026abbvie,novartis,BioPharma and Tech News,Myasthenia Gravis,Sjögrens Disease,Immunology News,inflammatory bowel disease,IL-23 pathway,ianalumabC3 glomerulopathy,VYVGART

This week's Immunology edition covers major regulatory milestones, late-stage…

by LucidQuest

Neuroscience

Neuroscience Today—January 21, 2026

January 21, 2026migraine,multiple sclerosis,digital therapeutics,BioPharma and Tech News,Fibromyalgia,Caplyta,Neuroscience News,Tardive dyskinesia,Major depressive disorderAJOVY,INGREZZA

This edition spans clinical data in neurology and psychiatry, digital health…

by LucidQuest

Women's_Health

Women’s Health Video Recap—January 21, 2026

January 21, 2026Zycubo,Copper histidinate,HIV,AJOVY,migraine,Ultrahuman,multiple sclerosis,Click Therapeutics,digital therapeutics,CGRP,BioPharma and Tech News,Ultrahuman Ring Air,endometriosis,Lumateperone,WHO,Yeztugo,Caplyta,Sunlenca,lenacapavir,HIV capsid,MHRA,Nexplanon,Women's Health News,Etonogestrel implant,Major depressive disorder,ParacetamolFremanezumab,Menkes disease

This biweekly Women’s Health video roundup spans regulatory actions, late-stage…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: GSK to acquire RAPT Therapeutics

January 21, 2026clinical trials,market access,Regulatory,immunology,biopharma,Lucid Diligence Brief,payer access,diligence,anti-IgE,food allergy,mergers and acquisitionspaediatrics

Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…

by Timos Papagatsias

Obesity Weekly News

Obesity Video Recap—January 20, 2026

January 20, 2026Alveus,GLP-1/GIP agonist,abbvie,ARO-INHBE,BioPharma and Tech News,Amylin receptor 3,GLP-1,Tirzepatide,Eli Lilly,Orforglipron,amylin,GIP,Obesity News,RNAi,Gubra,Structure TherapeuticsThermo Fisher,Nimbus Therapeutics

This biweekly Obesity video recap covers a mix of late-stage regulatory…

by LucidQuest

Endocrinology

Endocrinology Today—January 20, 2026

January 20, 2026BioPharma and Tech News,Tirzepatidetype 2 diabetes,type 1 diabetes,Acromegaly,Teplizumab,GLP-1 receptor agonist,Endocrinology News,insulin glargine,osteogenesis imperfecta,Marea Therapeutics

This week's Endocrinology roundup covers regulatory actions in Europe,…

by LucidQuest

Obesity Weekly News

Obesity Today—January 20, 2026

January 20, 2026wegovy,semaglutide,abbvie,BioPharma and Tech News,obesity,Novo Nordisk,Eli Lilly,GLP-1 receptor agonist,Obesity Newsoral GLP-1 therapies,amylin analog

This week's Obesity update covers a mix of regulatory decisions, late-stage…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T

January 20, 2026Oncology,clinical trials,market access,Regulatory,Cell Therapy,CAR T,biopharma,Lucid Diligence Brief,payer access,diligencehepatocellular carcinoma

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…

by Timos Papagatsias

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.